Please wait while the formulary information is being retrieved.
ZILEUTON ER (ZILEUTON)
- Maintenance therapy for asthma
600 mg tablet,extended release 12hr mphase
- 2 tablets (1,200 mg) by oral route 2 times per day within 1 hr after morning and evening meals
Maintenance therapy for asthma
- 2 tablets (1,200 mg) by oral route 2 times per day within 1 hr after morning and evening meals
- Orap
- pimozide
Contraindicated
- tizanidine
- Zanaflex
Severe
Moderate
- aminophylline
- Azilect
- Elixophyllin
- Inderal La
- Inderal Xl
- Innopran Xl
- Juxtapid
- lomitapide
- propranolol
- propranolol-hydrochlorothiazid
- rasagiline
- Theo-24
- Theochron
- theophylline
- theophylline in dextrose 5 %
- Abnormal hepatic function tests
- Disease of liver
Contraindicated
- None
Severe
Moderate
- Anxiety disorder
- Depression
- Dream disorder
- Hallucinations
- Mood changes
- Nervousness
- Suicidal ideation
- Tremor
ZILEUTON ER (ZILEUTON)
- Maintenance therapy for asthma
- None
- Dyspepsia
- Nasal passage irritation
- Nausea
- Sinusitis
- Sore throat
More Frequent
Severe
Less Severe
- Abnormal hepatic function tests
- Disease of liver
- Abdominal pain with cramps
- Diarrhea
- Headache disorder
- Myalgias
- Skin rash
- Upper respiratory infection
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Suicidal
- Suicidal ideation
Less Severe
- Aggressive behavior
- Agitation
- Depression
- Dream disorder
- Hallucinations
- Insomnia
- Irritability
- Nervousness
- Symptoms of anxiety
- Tremor
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Zileuton
Not studied age< 12 years. Potential risk of hepatotoxicity.
Monitor liver function. Observe for behavioral changes, sleep disorder.
- 1 Day – 12 Years
- Not studied age< 12 years. Potential risk of hepatotoxicity.
- Monitor liver function. Observe for behavioral changes, sleep disorder.
- 12 Years – 18 Years
- Not studied age< 12 years. Potential risk of hepatotoxicity.
- Monitor liver function. Observe for behavioral changes, sleep disorder.
Zileuton
- Severity Level:
2
- Additional Notes: Animal data suggest dev toxicity at doses similar to the recommended human dose.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Zileuton
Insufficient data available.
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available. |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Zileuton
Elderly females, age >65 years, have a greater risk for ALT elevation.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | Y | N | N | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Maintenance therapy for asthma | |
| J45 | Asthma |
| J45.2 | Mild intermittent asthma |
| J45.20 | Mild intermittent asthma, uncomplicated |
| J45.3 | Mild persistent asthma |
| J45.30 | Mild persistent asthma, uncomplicated |
| J45.4 | Moderate persistent asthma |
| J45.40 | Moderate persistent asthma, uncomplicated |
| J45.5 | Severe persistent asthma |
| J45.50 | Severe persistent asthma, uncomplicated |
| J45.9 | Other and unspecified asthma |
| J45.90 | Unspecified asthma |
| J45.909 | Unspecified asthma, uncomplicated |
| 0-9 | A-Z |
|---|---|
| J45 | Asthma |
| J45.2 | Mild intermittent asthma |
| J45.20 | Mild intermittent asthma, uncomplicated |
| J45.3 | Mild persistent asthma |
| J45.30 | Mild persistent asthma, uncomplicated |
| J45.4 | Moderate persistent asthma |
| J45.40 | Moderate persistent asthma, uncomplicated |
| J45.5 | Severe persistent asthma |
| J45.50 | Severe persistent asthma, uncomplicated |
| J45.9 | Other and unspecified asthma |
| J45.90 | Unspecified asthma |
| J45.909 | Unspecified asthma, uncomplicated |
Formulary Reference Tool